RecruitingNot ApplicableNCT06968689

Spatiotemporal Thalamocortical Alterations Underlie Experimental and Chronic Pain

Spatiotemporal Thalamocortical Alterations Underlie Experimental and Chronic Pain - Phase II


Sponsor

The University of Texas Health Science Center, Houston

Enrollment

60 participants

Start Date

Jun 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess thalamocortical (TC) connectivity during tonic pressure pain, to evaluate alpha activity during tonic pressure pain and to determine pressure pain ratings by using Electroencephalography (EEG), Functional Magnetic Resonance Imaging (fMRI), Transcranial Alternating Current Stimulation (tACS), sham and Transcranial random noise stimulation (tRNS)


Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Sham, a medical device called transcranial alternating current stimulation (tACS), and others for people with pain. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEtranscranial alternating current stimulation (tACS)

Participants will get a personalized brain stimulation: a 2 milliampere (mA) oscillating current that matches their natural alpha brain wave frequency (8-12 Hz), determined by a quick 3-minute EEG before the session.

DEVICESham

Active sham stimulation with 60- second -tACS will be applied , then ramp down, and be reintroduced in the last 30 seconds to minimize awareness of the experimental condition

DEVICEtranscranial random noise stimulation (tRNS)

Participants will still get stimulation, but at random frequencies between 1 and 200 Hz (instead of targeted alpha waves).


Locations(1)

The University of Texas Health Science Center at Houston

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06968689


Related Trials